Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge

Still Company's Third-Biggest Seller

 
• By Kevin Grogan
  
shield
Novartis has successfully shielded Gilenya from generics • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapy Areas